Formulation, Characterization, and Stability of Protein Drugs : Case Histories /
| Corporate Author: | |
|---|---|
| Other Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
New York, NY :
Springer US : Imprint: Springer,
2002.
|
| Edition: | 1st ed. 2002. |
| Series: | Pharmaceutical Biotechnology,
9 |
| Subjects: |
Table of Contents:
- A Compendium and Hydropathy/ Flexibility Analysis of Common Reactive Sites in Proteins: Reactivity at Asn, Asp, Gin, and Met Motifs in Neutral pH Solution
- Characterization, Stability, and Formulations of Basic Fibroblast Growth Factor
- The Characterization, Stabilization, and Formulation of Acidic Fibroblast Growth Factor
- Stability, Characterization, Formulation, and Delivery System Development for Transforming Growth Factor-Beta1
- Stability and Characterization of Recombinant Human Relaxin
- Interferon-?-1b (Betaseron®): A Model for Hydrophobic Therapeutic Proteins
- Characterization, Formulation, and Stability of Neupogen® (Filgrastim), a Recombinant Human Granulocyte-Colony Stimulating Factor
- Development and Shelf-Life Determination of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (LEUKINE®, GM-CSF)
- Formulation Development of an Antifibrin Monoclonal Antibody Radiopharmaceutical
- Biophysical Characterization and Formulation of TP40: A Chimeric Protein that Requires a pH-Dependent Conformational Change for Its Biological Activity
- Stability Characterization and Formulation Development of Recombinant Human Deoxyribonuclease I [Pulmozyme®, (Dornase Alpha)].